Who are VARIVAX® 2016 Commercial Process's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/varivax-2016-commercial-process.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

VARIVAX® 2016 Commercial Process — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VARIVAX® 2016 Commercial Process (VARIVAX® 2016 Commercial Process) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live, attenuated vaccine. Area: Infectious Disease.

phase 3 Live, attenuated vaccine Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VARIVAX® 2016 Commercial Process (VARIVAX® 2016 Commercial Process) — Merck Sharp & Dohme LLC. VARIVAX is a live, attenuated vaccine that stimulates an immune response against the varicella-zoster virus.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VARIVAX® 2016 Commercial Process TARGET	VARIVAX® 2016 Commercial Process	Merck Sharp & Dohme LLC	phase 3	Live, attenuated vaccine
VN	VN	Biomedical Advanced Research and Development Authority	marketed	live, attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live, attenuated vaccine class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VARIVAX® 2016 Commercial Process — Competitive Intelligence Brief. https://druglandscape.com/ci/varivax-2016-commercial-process. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing